EOFlow Co., Ltd., o se kamupani o lo'o tu'uina atu vaifofo tu'uina atu vaila'au fa'alavalava, ua fa'ailoa mai i aso nei o lana lala atoa a le US, EOFlow Inc. ua sainia se maliliega e fa'atūina se pisinisi fa'atasi i le US ma le UK biotech firm Zihipp Limited, o se vili. mai le Imperial College London.
O le fa'atulagaina fa'atatau o analogues e fa'asilisiliina ai mo le fa'aauauina o le tu'uina atu i lalo o le pa'u ma fa'ataga ai le tu'uina o vaila'au e fa'atatau i le metabolism o se tagata ma'i fa'apitoa, fa'avave le pa'u o le mamafa a'o aloese mai a'afiaga leaga mai le soona fai. EOFlow o le a tuʻuina atu se faʻatupega muamua ma lona EOPatch faʻapipiʻiina vailaʻau tuʻuina atu aʻo tuʻuina atu e Zihipp ana analogues peptide faʻapitoa ma le lagolago a le falemaʻi mo SanPlena. O le Ofisa Sili o Pulega a le EOFlow, Jesse J. Kim, o le a tauaveina le matafaioi o le Pule Sili na faavaeina o SanPlena ae o le vaega o totoe o le au pulega o le a faʻamaopoopoina e le aufaigaluega sinia mai Zihipp ma EOFlow.
O le Zihipp ose kamupani fa'akomepiuta a Peretania lea na vili mai le Imperial College London i le 2012. Ta'ita'ia e le polofesa fa'aaloalogia o Sir Stephen R. Bloom ma se vaega su'esu'e i le lalolagi, o lo'o fa'atupuina e le kamupani ni hormones peptide e fa'afetauia ai le maualuga o le ma'i suka ma le tino puta. Polofesa Sir Stephen R. Bloom o se tasi o tagata tomai faapitoa i le tino puta i le lalolagi ma o ana suʻesuʻega na taulaʻi i hormones o le manava e pulea ai le manaʻo ma le metabolism. E lauiloa o ia o se tagata faʻapitoa i le fausiaina o le maketi o le maʻisuka faʻavae hormone ma le obesity. Polofesa Sir Stephen Bloom o le ulu o le Atinaʻeina o Fualaau, Matagaluega o Metabolism, Digestion & Reproduction i le Imperial College London ma le faatonu o suʻesuʻega mo North West London Pathology i Imperial College Healthcare NHS Trust, o loʻo tautua i falemaʻi tetele e ono.
Ua atiae e Zihipp nisi o sui fou o fualaau faasaina peptide ua sili ona lelei mo le tino puta ma le NASH (Non-Alcoholic Steatohepatitis) togafitiga e tutusa ma hormones e taofia ai le manaʻo e pei o le oxyntomodulin ma le peptide YY lea ua faʻamaonia e ala i faʻataʻitaʻiga falemaʻi. O nei analogues ua sili ona lelei mo le faʻaauau pea o le tuʻuina atu o le subcutaneous e aloese ai mai aʻafiaga masani e fesoʻotaʻi ma tui i aso taʻitasi poʻo vaiaso o vailaʻau tutusa. O lo'o fa'amoemoe le SanPlena e fa'aogaina le lelei o le EOFlow's wearable, numera o le soifua maloloina fa'avae e iloa ai le folafolaga a nei sui i le fa'aolaina vave ma le pa'u mamafa; e oo atu i le 15% o le mamafa o le tagata i totonu ole 2-3 masina.
E tusa ai ma le Faalapotopotoga o le Soifua Maloloina a le Lalolagi (WHO) ma le International Association for the Study of Obesity (IASO), i le 2016, e sili atu i le 1.9 piliona tagata matutua, 18 tausaga pe sili atu, na mamafa tele ma o nei mea, 650 miliona (34%) o loʻo mamafa. O togafitiga o lo'o avanoa mo le tino puta e fa'atapula'a i tau, vave, aoga ma le fa'aauau. Mo se fa'ata'ita'iga, o vaila'au o lo'o iai mo le pa'u o le mamafa e mafai ona sili atu ma le tausaga e maua ai le 10-15% o le pa'u mamafa fa'atasi ai ma a'afiaga ogaoga o le manava. O le SanPlena platform fou o lo'o tautuaina se mana'oga tele e le'i fa'amalieina mo togafitiga fou ma fou mo le pa'u mamafa.
OA MEA E AVEA MAI LENEI TUSI:
- Kim, will assume the role as the founding CEO of SanPlena while the rest of the executive team will be rounded out by senior staff from both Zihipp and EOFlow.
- has signed an agreement to establish a joint venture in the US with the UK biotech firm Zihipp Limited, a spin out from Imperial College London.
- Proprietary formulation of the analogues optimizes them for continuous subcutaneous delivery thus allowing the drug dosing to be tailored to a particular patient’s metabolism, speeding weight loss while avoiding adverse effects from over-dosing.
